This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Starling Oncology, Inc.
11/5/2026
Please note that this call is being recorded and I'll be standing by should you need any assistance. It is now my pleasure to turn the meeting over to Minh Merchant. Please go ahead.
Thank you, Operator, and good afternoon, everyone. Welcome to Starling Oncology's third quarter 2026 Earnings Conference Call. I'm Minh Merchant, Chief Legal Officer, and joining me today are Dan Virnich, our Chief Executive Officer, and Rob Carter, our Chief Financial Officer. The press release announcing our results for the third quarter of 2026 is available in the investor relations section of our website, starlingoncology.com. A replay of this call will also be available on our website following its conclusion. Before we get started, I'd like to remind you of the company's State Harbor language included on our press release for the third quarter of 2026. Management may make forward-looking statements, including guidance and underlying assumptions. These forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, please see our filings of the SEC, including our most recent Form 10-K and subsequent Form 10-Q. This call will also discuss non-GAAP financial measures, such as adjusted EBITDA, MLR, and free cash flows. A reconciliation of these non-GAAP measures to the most comparable GAAP measures is included in the earnings release furnished to the SEC and available on our website. With that, I'll turn the call over to Dan.
Thank you, Minh. Good afternoon, everyone, and thank you for joining our third quarter of 2026 earnings call. I'm excited to report that we delivered another quarter of record revenue of $169.8 million, an increase of 24% year over year and adjusted EBITDA of $3.4 million, meaningfully above the top end of the Q3 range we provided on our last fall. This is our second consecutive quarter of positive adjusted EBITDA, and we are reaffirming full-year adjusted EBITDA positivity in 2026. In addition to our strong financial performance, we have a number of positive updates today on our performance, including growth in capitated relationships, performance of our pharmacy, As well as strong data on utilization management effectiveness, we are seeing from Starlink Nexus, our recently launched provider portal. We continue to make meaningful progress in what is a pivotal year for our company as we look for profitability, realize operating leverage for our growth and growing scale, and stabilize our balance sheet. Let me start with an update on Starlink Nexus, our proprietary utilization management portal that we announced the launch of in early August. Starling Nexus is now live for our network providers who practice in all markets where we have delegated capitation arrangements and in the interface through which prior authorizations are submitted for UN review. This currently includes contracts previously announced on prior calls in Florida, as well as our first delegated capitation contract outside of Florida, which went effective October 1, 2026, the Health Plan in Oregon, where we have a statewide contract for Medicare Advantage with approximately 40,000 incremental spots. We are encouraged by early data on how effective Nexus will be for implementation of our UM program over non-avoid providers. Currently, over 300 network practices have the ability to access the platform, and we are seeing over half of first-pass submission adherence for our therapeutic pathways with over 90% formulary adherence on authorizations which require substitution after initial review. In addition, our data shows we are implementing highly compliant and fast UM operations at scale, with over 99.2% compliance on over 4,000 authorizations in Florida this year alone, and an average UM decision time of 13 hours after submission, which is incredibly fast by health plan standards and aligns with our mission to provide better access to care for the populations that we serve. A major strategic goal of Starlink Nexus in upcoming years is to increase access to ancillary services As well as help grow revenue and profitability from these important services for our investors. As noted on our last call, we are now live with the first ancillary service enhancement, which is access to Part D electronic prescribing in the portal for practices that wish to select Starling as pharmacy of choice. We'll be engaging with network practices to help drive awareness of this fast and convenient service in Q4. This will be an incremental growth channel for our Part D business going forward. Other services on the roadmap for integration in the upcoming year include centralized clinical trials access and care navigation. Stepping back from Nexus, I also want to call out the performance of our capitated business overall. Capitated revenue grew 40% year-over-year in the third quarter, and our medical loss ratio, or MLR, improved sequentially to 81% from 85.5% in the second quarter, slightly better than we had anticipated. We believe this is yet another proof point of our ability to effectively manage oncology cost of care at Dale for our patient and payer partners. Turning to our Part B specialty pharmacy business, continued increase in the capture rate of the bills written by Starling physicians was the primary contributor to year-over-year revenue growth in the specialty pharmacy as the team has implemented technology and human capital-driven workflows to operationalize the ease and benefit of Starling providers and patients utilizing our captive pharmacy for their specialty medication needs. Additionally, Starlane is seeing more new patients for treatment planning services, particularly as a result of growth in capitated lives pursuant to new contract rent, which is driving first-time bills into our pharmacy as we deliver on our customer service model and overall value proposition of specialty pharmacy as a core part of our integrated care model. Revenue from Part D in the third quarter was $109 million, up 44% year-over-year, and gross margin was an incredible 24%. We are in a unique position to manage drug margins through our sales procurement, robust internal analytics on pricing, and active utilization management efforts. Rob will provide more detail on these efforts in a few minutes. While this was an exceptional quarter for Part D margins, we expect margins to likely normalize in the high teens percent range long term. Turning to our pipeline of new contracts, we have a number of topics to highlight. Capitated revenue and capitated lives are both up year-over-year 40% and 10% respectively, driven by the growth we've experienced in both our narrow and delegated relationships across states. On October 1st, we celebrated a milestone for Starling by starting our first delegated capitation contract outside of Florida in our Oregon market through a statewide health plan relationship covering their approximately $40,000 Medicare Advantage class. In Florida, we now have a fully contracted statewide provider network ready to serve any payer that we partner with. and we have several additional opportunities in our pipeline with new health plan partners as we look to 2027. We continue to serve three anchor health plan partners through delegated capitation across five counties as of this call and for reasons unrelated to Starlink performance will not be immediately expanding statewide with these partners. Looking forward, we continue to anticipate capitated revenue growth of 100% in 2027 versus 2026. and known addressable opportunities in our current 2027 pipeline exceed $1 billion to annualized spend, including several high-quality opportunities outside of our current five states. While we will not execute on 100% of the addressable pipeline, it highlights the increasing demand for our services and ongoing scalability of Starlink over the next several years while mitigating customer concentration in any one market or health plan partner. To wrap up, in our third quarter, we exceeded our guidance on adjusted EBITDA and set new records for total revenue and Part D growth for our business. We expanded our delegated capitation model to a new state, while continuing to reduce MLR towards the lower end of our guided range, and we are well positioned to deliver on full-year adjusted EBITDA positivity for 2026 within our prior guidance. We are seeing tremendous early results from Nexus in terms of network provider performance on formulary adherence, and we are just starting to tap into other ancillary service opportunities in the network. Thank you, Dan, and good afternoon, everyone. On the call today, I will review our third quarter financial results, touch on our balance sheet and cash flow, and close with our guidance and outlook. Total revenues for the third quarter was $169.8 million, compared to $137 million.
You're reading a preview of the STLN Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing